>
Will China Retaliate Against Donald Trump's Oil Blockade and Force an American Surrender?
There can be no peace in the Middle East as long as the Zionist agenda of greater Israel rules
Elon Musk Reveals Covid Vaccine Injury After Former Pfizer Official Admits Shots Likely Killed...
Autonomous wing-in-ground effect aircraft has US military in its sights
The Most Dangerous Race on Earth Isn't Nuclear - It's Quantum.
This Plasma Stove Cooks Hotter Than The Sun
Energy storage breakthrough traps sunlight in a molecule
Steel rebar may have met its match – in the form of wavy plastic
Video: Semicircular wings give Cyclone VTOL a different kind of lift
After 20 Years, Wave Energy Finally Works
FCC Set To "Supercharge" Starlink Space Internet With "Seven-Fold More Capacity"
'World's First' Humanoid Robot For Real Household Chores Launched With 16-Hour Battery
XAI Training 10 Trillion Parameter Model – Likely Out in Mid 2026

Two adults with leukaemia have been in remission since 2010 after Car-T therapy.
It involves removing blood and genetically modifying its white cells so they target cancer.
The resulting Car-T cells are re-injected in a type of immunotherapy which uses the body's immune system to attack tumours.
Levels of the cells in the two cured patients remain high.
Dr Carl June, of the University of Pennsylvania, US, said: "Based on these results, we can conclude that Car-T cells can cure leukaemia.
"These cells continued to demonstrate tumour-killing characteristics."
Patient Doug Olsen said medics could not find any cancer after a few weeks. He said: "I knew the doctors weren't sure but I was pretty convinced that I was done with cancer."
The NHS offers Car-T to some children with leukaemia and adults with lymphoma.
It warns the therapy can make the immune system over-react or trigger side effects such as fever, vomiting or breathing difficulties.